Skip to main content

Table 1 Characteristics of studies included in the analysis

From: Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis

Reference Country Study Design Subjects (number) Menopausal Condition PreM/PostM Index Tests (Methods) Cut-off Value Proven cancer N (%)
Abdel-Azeez et al., 2010 Egypt Cross-section 65 18/47 HE4 (EIA); CA125 (ECLIA) HE4: 72pM; CA125: 35U/mL OC: 41 (63.1%)
Bandiera et al., 2011 Italy Cross-section 419 134/284 (1 patient with unknown stage was not analyzed) ROMA ROMA: preM 7.4% postM 25.3%; EOC: 114 (27.2%)
      HE4 (CMIA); HE4: preM 70pM, postM 140pM;  
      CA125 (CMIA) CA125: 35U/mL  
Chang et al., 2011 China Cross-section 118 - HE4 (EIA); CA125 (EIA) HE4: 150pM; CA125: 35U/mL OC: 52 (44.1%)
Holcomb et al., 2011 USA Cross-section 229 229/- HE4 (CMIA); CA125 (CMIA) HE4: 70pM; CA125: 35U/mL EOC: 18 (7.86%)
Jacob et al., 2011 Switzerland Cross-section 160 84/76 ROMA ROMA: 13.1% EOC: 29 (18.1%)
      HE4 (ELISA); CA125 (ELISA) HE4: 70pM; CA125: 35U/mL OC: 56 (35%)
Kim et al., 2011 Korea Cross-section 159 51/108 ROMA ROMA: preM 7.6% postM 10.9%; EOC: 72 (45.3%)
      HE4 (CMIA); CA125 (CMIA) HE4: 70pM; CA125: 35 IU/mL OC: 78 (49.1%)
Montagnana et al., 2011 Italy Cross-section 104 51/53 ROMA ROMA: preM12.5% postM14.4%; EOC: 55 (52.9%)
      HE4 (EIA); CA125 (CLEIA) HE4: 74.2pM; CA125: 35U/mL  
Moore et al., 2008 USA Cross-section 233 - HE4 (EIA); CA125 (RIA) - EOC: 67 (28.8%)
Moore et al., 2009 USA Cross-section 531 248/283 ROMA ROMA: preM 13.1% postM 27.7% EOC: 129 (26.8%)
      HE4 (EIA); CA125 (CMIA)   OC: 154 (29.0%)
Moore et al., 2011 USA Cross-section 472 255/217 ROMA ROMA: preM 13.1%; postM 27.7% EOC: 48 (10.2%)
      HE4 (ELISA); CA125 (CMIA)   
Van Gorp et al., 2011 Belgium Cross-section 389 184/205 ROMA ROMA: preM 12.5% postM 14.4%; OC: 161 (41.4%)
      HE4 (EIA); CA125 (EIA) HE4: 70pM;CA125: 35U/mL  
  1. PreM: premenopause; PostM: postmenopause; ROMA: Risk of Ovarian Malignancy Algorithm; HE4: Human Epididymis Protein 4; CA125: Cancer Antigen 125; EOC: epithelial ovarian cancer; OC: ovarian cancer; EIA: enzyme immunoassay; CLEIA: chemilumenscence enzyme immunoassay; CMIA: chemiluminescent microparticle immunoassay; ECLIA: electrochemilumenscence immunoassay; RIA: radioimmunoassay; ELISA: enzyme-linked immunoadsorbent assay. -: not mentioned.